Oral Proteins and Peptides Market to Hit USD 20.36 Billion by 2029 with 22.5% CAGR | MarketsandMarkets | PR Newswire [Video]

, /PRNewswire/ — The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 billion by 2029, with a compound annual growth rate (CAGR) of 22.5% from 2024 to 2029. Robust clinical trial pipeline for oral proteins and peptides drugs and increasing investment and funding for research and development and awareness and adoption of oral proteins and peptides among pharmaceutical and biotechnology companies for research. On the other hand, contraindication of oral proteins and peptides and availability of alternative therapies are hampering the market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194705708

Browse in-depth TOC on “Oral Proteins and Peptides Market“

407 – Tables

53 – Figures

318 – Pages

Based on molecule, the oral proteins and peptides market is segmented into trofinetide, semaglutide, linaclotide, voclosporin, plecanatide, calcitonin and others. The semaglutide segment accounted for the largest share of the oral proteins and peptides market. This can be owing to increasing prevalence of diabetes and …